Duearity AB (publ) (DEAR.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -4.17 Million SEK | -305.25% |
| 2022 | -6.37 Million SEK | 58.45% |
| 2021 | -15.34 Million SEK | -1502.86% |
| 2020 | -957.37 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 56 Thousand SEK | 100.86% |
| 2024 Q1 | -6.53 Million SEK | 18.97% |
| 2023 FY | -25.83 Million SEK | -305.25% |
| 2023 Q2 | -1.69 Million SEK | -12.01% |
| 2023 Q1 | -1.51 Million SEK | 17.62% |
| 2023 Q4 | -8.06 Million SEK | -269.48% |
| 2023 Q3 | -2.18 Million SEK | -28.58% |
| 2022 Q4 | -1.83 Million SEK | -118.41% |
| 2022 FY | -6.37 Million SEK | 58.45% |
| 2022 Q1 | -2.11 Million SEK | 1.49% |
| 2022 Q3 | -842 Thousand SEK | 46.74% |
| 2022 Q2 | -1.58 Million SEK | 25.21% |
| 2021 Q3 | -2.68 Million SEK | 35.8% |
| 2021 FY | -15.34 Million SEK | -1502.86% |
| 2021 Q4 | -2.14 Million SEK | 20.01% |
| 2021 Q1 | -1.03 Million SEK | 0.0% |
| 2021 Q2 | -4.17 Million SEK | -304.16% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | -957.37 Thousand SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 178.875% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 101.39% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 101.39% |
| Arcoma AB | 11.07 Million SEK | 137.738% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 102.985% |
| BICO Group AB (publ) | 1.83 Billion SEK | 100.228% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 101.673% |
| CellaVision AB (publ) | 463.04 Million SEK | 100.902% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 239.406% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 85.296% |
| C-Rad AB (publ) | 66.01 Million SEK | 106.329% |
| Dignitana AB (publ) | 58.97 Million SEK | 107.085% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 90.005% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.031% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 91.68% |
| Iconovo AB (publ) | 17.57 Million SEK | 123.769% |
| Integrum AB (publ) | 690.56 Thousand SEK | 705.014% |
| Luxbright AB (publ) | -2.79 Million SEK | -49.381% |
| Mentice AB (publ) | 236.38 Million SEK | 101.767% |
| OssDsign AB (publ) | 83.64 Million SEK | 104.995% |
| Paxman AB (publ) | 12.61 Million SEK | 133.111% |
| Promimic AB (publ) | 38.51 Million SEK | 110.848% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 91.768% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 126.052% |
| ScandiDos AB (publ) | 47.55 Million SEK | 108.786% |
| Sectra AB (publ) | 557.55 Million SEK | 100.749% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 103.834% |
| Senzime AB (publ) | 8.33 Million SEK | 150.102% |
| SpectraCure AB (publ) | -9.22 Million SEK | 54.7% |
| Stille AB | 132.17 Million SEK | 103.161% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 100.211% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 101.002% |